BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Soleno Soars on Positive Prader-Willi Syndrome Data

  Soleno announced promising results of its diazoxide choline extended-release tablets in patients with Prader-Willi syndrome at ENDO 2022.

  June 14, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Business

  On a Partnering Spree, Evotec Announces New Janssen Alliance

  Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.

  June 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  FDA Agrees to Meet with Stealth on Barth Syndrome Drug

  On Tuesday, Stealth Biotherapeutics announced that it plans to meet with the FDA to discuss a potential NDA for its therapeutic, elamipretide, which is intended to treat Barth syndrome.

  June 14, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Policy

  UPDATE: In Unanimous Vote, FDA Advisory Committee Recommends Moderna’s COVID Vaccine for Kids 6-17

  In a unanimous vote, a panel of FDA advisors voted to recommend the approval of Moderna’s COVID-19 vaccine for children between the ages of six and 17 years old.

  June 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Emulate Launches Colon Intestine-Chip Assay to Predict Therapeutic Efficacy in IBD

  The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.

  June 14, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Researchers Link Mutations in Long Neglected Non-Coding Genome to Cancer

  Researchers from the Dana-Farber Cancer Institute looked deeper into a non-coding portion of the human genome, uncovering mechanisms that might drive or suppress cancer development.

  June 14, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Policy

  China Update: Pharma Downplays Challenges, Seeing Innovation Instead

  Despite geopolitical tensions, the pharmaceutical industry sees China as a land of opportunity and some largely surmountable challenges.

  June 14, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Eli Lilly’s Olumiant Becomes First Systemic Treatment for Alopecia Areata

  Eli Lilly’s Olumiant (baricitinib) received approval from the FDA for the treatment of severe alopecia areata, making it the first systemic treatment for adults living with the disease.

  June 14, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Alnylam Scores Another FDA Nod in hATTR

  The FDA has approved Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults.

  June 14, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Pfizer, MorphoSys and Incyte Take Aim at DLBCL in New Collab

  MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.

  June 14, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh